Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380785877> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4380785877 abstract "Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to reduce weight in patients with overweight or obesity. However, their effect on systolic blood pressure (SBP) remains less well-established. We conducted a network meta-analysis to evaluate the effect of different drug-dose combinations of GLP-1 RAs on SBP in this population. Methods: Electronic databases were searched through January 2022 for RCTs which evaluated the efficacy of different doses of semaglutide, liraglutide, efpeglenatide, and exenatide in obese patients with and without T2DM. Systolic blood pressure (SBP) was chosen as the primary endpoint. A frequentist network meta-analysis using random-effects model was conducted, and pooled estimates were reported as mean differences (MD) with 95% confidence intervals (CI). Results: A total of 20 RCTs were included in the analysis. Among individuals with T2DM, liraglutide <2 mg once daily (QD) showed the greatest reduction in SBP (MD: -3.78 [-5.63; -1.15]), followed by exenatide 10 ug twice daily (BID) (MD: -3.39 [-5.63; -1.15]), and semaglutide ≥1mg once weekly (QW) (MD: -3.28 [–5.68; –0.88]), when compared with placebo. Among individuals without diabetes, efpeglenatide ≤ 6 mg QW showed the greatest reduction in SBP (MD: -6.00 [-9.89; -2.11]), followed by semaglutide ≥ 1 mg QW (MD: -4.54 [–5.69; –3.39]), and semaglutide <1mg QW (MD: -4.51 [–5.49; –3.54]). The figure shows how each drug/dose combination compares with others. Conclusions: This network meta-analysis suggests liraglutide <2mg QD is the most efficacious GLP-1 RA in lowering SBP in obese patients with T2DM. For obese patients without diabetes, efpeglenatide ≤6mg QW is the most effective." @default.
- W4380785877 created "2023-06-16" @default.
- W4380785877 creator A5003663671 @default.
- W4380785877 creator A5008189923 @default.
- W4380785877 creator A5014514646 @default.
- W4380785877 creator A5041493580 @default.
- W4380785877 creator A5053329002 @default.
- W4380785877 date "2022-11-08" @default.
- W4380785877 modified "2023-09-24" @default.
- W4380785877 title "Abstract 15922: Effect of Glp-1 Receptor Agonists on Systolic Blood Pressure in Patients With Overweight or Obesity: A Network Meta-Analysis" @default.
- W4380785877 doi "https://doi.org/10.1161/circ.146.suppl_1.15922" @default.
- W4380785877 hasPublicationYear "2022" @default.
- W4380785877 type Work @default.
- W4380785877 citedByCount "0" @default.
- W4380785877 crossrefType "journal-article" @default.
- W4380785877 hasAuthorship W4380785877A5003663671 @default.
- W4380785877 hasAuthorship W4380785877A5008189923 @default.
- W4380785877 hasAuthorship W4380785877A5014514646 @default.
- W4380785877 hasAuthorship W4380785877A5041493580 @default.
- W4380785877 hasAuthorship W4380785877A5053329002 @default.
- W4380785877 hasConcept C126322002 @default.
- W4380785877 hasConcept C134018914 @default.
- W4380785877 hasConcept C142724271 @default.
- W4380785877 hasConcept C204787440 @default.
- W4380785877 hasConcept C27081682 @default.
- W4380785877 hasConcept C2777180221 @default.
- W4380785877 hasConcept C2780533449 @default.
- W4380785877 hasConcept C2780586474 @default.
- W4380785877 hasConcept C2781308992 @default.
- W4380785877 hasConcept C2908647359 @default.
- W4380785877 hasConcept C2909862629 @default.
- W4380785877 hasConcept C511355011 @default.
- W4380785877 hasConcept C555293320 @default.
- W4380785877 hasConcept C71924100 @default.
- W4380785877 hasConcept C84393581 @default.
- W4380785877 hasConcept C95190672 @default.
- W4380785877 hasConcept C99454951 @default.
- W4380785877 hasConceptScore W4380785877C126322002 @default.
- W4380785877 hasConceptScore W4380785877C134018914 @default.
- W4380785877 hasConceptScore W4380785877C142724271 @default.
- W4380785877 hasConceptScore W4380785877C204787440 @default.
- W4380785877 hasConceptScore W4380785877C27081682 @default.
- W4380785877 hasConceptScore W4380785877C2777180221 @default.
- W4380785877 hasConceptScore W4380785877C2780533449 @default.
- W4380785877 hasConceptScore W4380785877C2780586474 @default.
- W4380785877 hasConceptScore W4380785877C2781308992 @default.
- W4380785877 hasConceptScore W4380785877C2908647359 @default.
- W4380785877 hasConceptScore W4380785877C2909862629 @default.
- W4380785877 hasConceptScore W4380785877C511355011 @default.
- W4380785877 hasConceptScore W4380785877C555293320 @default.
- W4380785877 hasConceptScore W4380785877C71924100 @default.
- W4380785877 hasConceptScore W4380785877C84393581 @default.
- W4380785877 hasConceptScore W4380785877C95190672 @default.
- W4380785877 hasConceptScore W4380785877C99454951 @default.
- W4380785877 hasIssue "Suppl_1" @default.
- W4380785877 hasLocation W43807858771 @default.
- W4380785877 hasOpenAccess W4380785877 @default.
- W4380785877 hasPrimaryLocation W43807858771 @default.
- W4380785877 hasRelatedWork W2786247186 @default.
- W4380785877 hasRelatedWork W2884645397 @default.
- W4380785877 hasRelatedWork W2913046323 @default.
- W4380785877 hasRelatedWork W2963614034 @default.
- W4380785877 hasRelatedWork W2979558564 @default.
- W4380785877 hasRelatedWork W2993091388 @default.
- W4380785877 hasRelatedWork W3137323645 @default.
- W4380785877 hasRelatedWork W3166343083 @default.
- W4380785877 hasRelatedWork W4289779349 @default.
- W4380785877 hasRelatedWork W4379233206 @default.
- W4380785877 hasVolume "146" @default.
- W4380785877 isParatext "false" @default.
- W4380785877 isRetracted "false" @default.
- W4380785877 workType "article" @default.